A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2017

At a glance

  • Drugs Vesatolimod (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 12 Apr 2017 Planned End Date changed from 1 Sep 2018 to 1 May 2019.
    • 12 Apr 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Apr 2019.
    • 12 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top